Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000908406 | SCV001053163 | likely benign | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8 | 2024-01-07 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV001818806 | SCV002066553 | uncertain significance | not specified | 2017-08-07 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003958276 | SCV004767662 | likely benign | POMGNT2-related disorder | 2022-08-09 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Ophthalmology Lab, |
RCV004731059 | SCV005326282 | likely pathogenic | concomitant exotropia | 2024-08-30 | no assertion criteria provided | clinical testing | Dominant inheritance. POMGNT2 (protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4)), is the pedigree coisolation gene in F10 (c.1181G>A(p.R394Q)). The variant was not detected in 422 sporadic concomitant exotropia samples and 239 normal samples. Subsequent capture and sequencing results showed that 4 different SNP mutations were acquired in 220 sporadic samples. The results show that POMGNT2 has a variety of mutations in concomitant exotropia, and it could be an underlying pathogenic gene. POMGNT2 is a protein-coding gene associated with muscular dystrophy-dystroglycanopathy. This is consistent with muscular factors related to the pathogenesis of strabismus. |